RP Stock Overview
A regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
RepliCel Life Sciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.01 |
| 52 Week High | US$0.10 |
| 52 Week Low | US$0.01 |
| Beta | 0.95 |
| 11 Month Change | -50.00% |
| 3 Month Change | n/a |
| 1 Year Change | -81.82% |
| 33 Year Change | -96.67% |
| 5 Year Change | -96.00% |
| Change since IPO | -99.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| RP | CA Life Sciences | CA Market | |
|---|---|---|---|
| 7D | 0% | 3.9% | 1.3% |
| 1Y | -81.8% | 4.7% | 23.7% |
Return vs Industry: RP underperformed the Canadian Life Sciences industry which returned 4.7% over the past year.
Return vs Market: RP underperformed the Canadian Market which returned 23.7% over the past year.
Price Volatility
| RP volatility | |
|---|---|
| RP Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 8.9% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CA Market | 17.5% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: RP's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: Insufficient data to determine RP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Andrew Schutte | www.replicel.com |
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy to treat tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons. The company’s product candidates include RCH-01, a cell therapy for pattern baldness; RCS-01, a cell therapy foraging or sun damaged skin; and RCT-01, a cell therapy for tendon degeneration.
RepliCel Life Sciences Inc. Fundamentals Summary
| RP fundamental statistics | |
|---|---|
| Market cap | CA$191.21k |
| Earnings (TTM) | CA$1.37m |
| Revenue (TTM) | CA$353.74k |
0.1x
P/E Ratio0.5x
P/S RatioIs RP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RP income statement (TTM) | |
|---|---|
| Revenue | CA$353.74k |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$353.74k |
| Other Expenses | -CA$1.01m |
| Earnings | CA$1.37m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.021 |
| Gross Margin | 100.00% |
| Net Profit Margin | 386.01% |
| Debt/Equity Ratio | -25.2% |
How did RP perform over the long term?
See historical performance and comparison